Tandem Diabetes Care | TNDM - Operating Profit


Tandem Diabetes Care reported $-22.86M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
Align Technology USD 224.71M 40.06M Dec/2025
AtriCure USD 208K 4.03M Sep/2025
Baxter International USD 201.2M 70.8M Sep/2025
Becton, Dickinson and Co. USD 826M 153M Sep/2025
Boston Scientific USD 1.24B 203M Dec/2025
Cooper Companies USD 140.4M 35.3M Sep/2025
Dexcom USD 242.5M 29.9M Sep/2025
Edwards Lifesciences USD 425.1M 5.8M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Globus Medical USD -117.52M 8.43M Sep/2025
ICU Medical USD 26.86M 52K Sep/2025
Insulet USD 117.7M 3.4M Sep/2025
Integra LifeSciences USD 11.76M 13.07M Sep/2025
Intuitive Surgical USD 865.3M 97.5M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Masimo USD 83.6M 19.1M Sep/2025
Medtronic USD 1.7B 100M Sep/2025
Merit Medical Systems USD 42.61M 4.41M Sep/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Stryker USD 1.97B 609M Dec/2025
Tandem Diabetes Care USD -22.86M 9M Sep/2025
Teleflex USD -408.9M 586.38M Sep/2025
Zimmer Biomet Holdings USD 338.3M 58.1M Sep/2025